New panel tackles clinical research funding cuts

Article Abstract:

A National Institutes of Health (NIH) advisory group is working to ensure adequate funding for clinical research. In July of 1995, a 14-member panel convened to review and resolve problems that face clinical research in the cost-cutting managed care environment. While industry, managed care, academia, and public health groups voice keen support for clinical research, federal funding remains a primary concern. The original Congressional budget proposal for the NIH recommended a 5% funding cut for the upcoming fiscal year. Policymakers have different perspectives on the government's role in biomedical research. Because there is no public policy that supports academic medical centers, the marketplace drives clinical research funding. The panel will seek non-NIH funds for clinical research, examine the NIH's funding mechanisms, analyze clinical research training programs, and examine the General Clinical Research Centers.

Economic aspects, Finance, Medical research, United States. National Institutes of Health, Federal aid to medical research, Medical research assistance

---

Consensus Panel Considers Osteoporosis

Article Abstract:

A consensus conference convened by the National Institutes of Health has published its recommendations on preventing, diagnosing and treating osteoporosis. Osteoporosis is a loss of bone that can lead to bone fractures. It can affect many people of all ages, but is most commonly studied in postmenopausal women. About 18 million Americans have low bone mass and another 10 million have osteoporosis. The treatment of osteoporosis-related fractures costs $10 to $15 billion in the US each year. Adequate dietary calcium, vitamin D, and exercise are the best ways of preventing osteoporosis.

Care and treatment, Reports, Practice guidelines (Medicine), Osteoporosis

---

FDA Calls Bovine-Based Vaccines Currently Safe

Article Abstract:

Experts on the vaccine manufacturing process have told the US FDA that all vaccines currently in use do not pose a health hazard. The FDA had urged all manufacturers not to use animal products in their vaccines that came from countries affected by mad cow disease.

Safety and security measures, Risk factors, Vaccines industry, Biological products industry, Science and technology policy, Vaccines, Creutzfeldt-Jakob disease, United States. Food and Drug Administration

Similar abstracts:

• Abstracts: S.C. med center to appeal ruling against lease with Columbia. Regents, system agree not to sell Baylor medical center
• Abstracts: GWU-Universal deal cleared despite lingering concerns. Calif. merger expected to usher in new environment. Hospital finds new buyer: medical staff concerns prompt new affiliation
• Abstracts: Shattuck lecture - biomedical research enters the steady state. The relation between funding by the National Institutes of Health and the burden of disease
• Abstracts: The battle for hearts and minds. 'Psycho' headlines add to mental illness misery
• Abstracts: Schizophrenia Researchers Striving for Early Detection and Intervention. Delay in Treating Schizophrenia May Narrow Therapeutic Window of Opportunity

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.